Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT

Nico Gagelmann, Diderik Jan Eikema, Simona Iacobelli, Linda Koster, Hareth Nahi, Anne Marie Stoppa, T. Masszi, Denis Caillot, Stig Lenhoff, M. Udvardy, Charles Crawley, William Arcese, Clara Mariette, Ann Hunter, Xavier Leleu, Martin Schipperus, Michel Delforge, Pietro Pioltelli, John A. Snowden, Maija Itälä-RemesMaurizio Musso, Anja van Biezen, Laurent Garderet, Nicolaus Kröger

Research output: Article

5 Citations (Scopus)

Abstract

We investigated extramedullary disease in newly diagnosed multiple myeloma patients and its impact on outcome following first-line autologous stem cell transplantation. We identified 3744 adult myeloma patients who received up-front single (n=3391) or tandem transplantation (n=353) between 2005 and 2014 with available data on extramedullary involvement at diagnosis. The overall incidence of extramedullary disease was 18.2% (n=682) and increased per year from 6.5% (2005) to 23.7% (2014). Paraskeletal involvement was found in 543 (14.5%) and extramedullary organ involvement in 139 (3.7%). More patients with extramedullary organ involvement had multiple involved sites (≥2; P<0.001). In a comparison of patients with single sites with patients without the disease, up-front transplantation resulted in at least similar 3-year progression-free survival (paraskeletal: P=0.86, and extramedullary organ: P=0.88). In single paraskeletal involvement, this translated less clearly into worse 3-year overall survival (P=0.07) while single organ involvement was significantly worse (P=0.001). Multiple organ sites were associated with worse outcome (P<0.001 and P=0.01). First-line treatment with tandem compared with single transplantation resulted in similar survival in patients with extramedullary disease at diagnosis (P=0.13 for both).

Original languageEnglish
Pages (from-to)890-897
Number of pages8
JournalHaematologica
Volume103
Issue number5
DOIs
Publication statusPublished - ápr. 30 2018

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Neoplasms
Transplantation
Survival
Disease-Free Survival
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation : A study from the chronic malignancies working party of the EBMT. / Gagelmann, Nico; Eikema, Diderik Jan; Iacobelli, Simona; Koster, Linda; Nahi, Hareth; Stoppa, Anne Marie; Masszi, T.; Caillot, Denis; Lenhoff, Stig; Udvardy, M.; Crawley, Charles; Arcese, William; Mariette, Clara; Hunter, Ann; Leleu, Xavier; Schipperus, Martin; Delforge, Michel; Pioltelli, Pietro; Snowden, John A.; Itälä-Remes, Maija; Musso, Maurizio; van Biezen, Anja; Garderet, Laurent; Kröger, Nicolaus.

In: Haematologica, Vol. 103, No. 5, 30.04.2018, p. 890-897.

Research output: Article

Gagelmann, N, Eikema, DJ, Iacobelli, S, Koster, L, Nahi, H, Stoppa, AM, Masszi, T, Caillot, D, Lenhoff, S, Udvardy, M, Crawley, C, Arcese, W, Mariette, C, Hunter, A, Leleu, X, Schipperus, M, Delforge, M, Pioltelli, P, Snowden, JA, Itälä-Remes, M, Musso, M, van Biezen, A, Garderet, L & Kröger, N 2018, 'Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT', Haematologica, vol. 103, no. 5, pp. 890-897. https://doi.org/10.3324/haematol.2017.178434
Gagelmann, Nico ; Eikema, Diderik Jan ; Iacobelli, Simona ; Koster, Linda ; Nahi, Hareth ; Stoppa, Anne Marie ; Masszi, T. ; Caillot, Denis ; Lenhoff, Stig ; Udvardy, M. ; Crawley, Charles ; Arcese, William ; Mariette, Clara ; Hunter, Ann ; Leleu, Xavier ; Schipperus, Martin ; Delforge, Michel ; Pioltelli, Pietro ; Snowden, John A. ; Itälä-Remes, Maija ; Musso, Maurizio ; van Biezen, Anja ; Garderet, Laurent ; Kröger, Nicolaus. / Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation : A study from the chronic malignancies working party of the EBMT. In: Haematologica. 2018 ; Vol. 103, No. 5. pp. 890-897.
@article{3b0122167d044a97b718cfd0184d2a4c,
title = "Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT",
abstract = "We investigated extramedullary disease in newly diagnosed multiple myeloma patients and its impact on outcome following first-line autologous stem cell transplantation. We identified 3744 adult myeloma patients who received up-front single (n=3391) or tandem transplantation (n=353) between 2005 and 2014 with available data on extramedullary involvement at diagnosis. The overall incidence of extramedullary disease was 18.2{\%} (n=682) and increased per year from 6.5{\%} (2005) to 23.7{\%} (2014). Paraskeletal involvement was found in 543 (14.5{\%}) and extramedullary organ involvement in 139 (3.7{\%}). More patients with extramedullary organ involvement had multiple involved sites (≥2; P<0.001). In a comparison of patients with single sites with patients without the disease, up-front transplantation resulted in at least similar 3-year progression-free survival (paraskeletal: P=0.86, and extramedullary organ: P=0.88). In single paraskeletal involvement, this translated less clearly into worse 3-year overall survival (P=0.07) while single organ involvement was significantly worse (P=0.001). Multiple organ sites were associated with worse outcome (P<0.001 and P=0.01). First-line treatment with tandem compared with single transplantation resulted in similar survival in patients with extramedullary disease at diagnosis (P=0.13 for both).",
author = "Nico Gagelmann and Eikema, {Diderik Jan} and Simona Iacobelli and Linda Koster and Hareth Nahi and Stoppa, {Anne Marie} and T. Masszi and Denis Caillot and Stig Lenhoff and M. Udvardy and Charles Crawley and William Arcese and Clara Mariette and Ann Hunter and Xavier Leleu and Martin Schipperus and Michel Delforge and Pietro Pioltelli and Snowden, {John A.} and Maija It{\"a}l{\"a}-Remes and Maurizio Musso and {van Biezen}, Anja and Laurent Garderet and Nicolaus Kr{\"o}ger",
year = "2018",
month = "4",
day = "30",
doi = "10.3324/haematol.2017.178434",
language = "English",
volume = "103",
pages = "890--897",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "5",

}

TY - JOUR

T1 - Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation

T2 - A study from the chronic malignancies working party of the EBMT

AU - Gagelmann, Nico

AU - Eikema, Diderik Jan

AU - Iacobelli, Simona

AU - Koster, Linda

AU - Nahi, Hareth

AU - Stoppa, Anne Marie

AU - Masszi, T.

AU - Caillot, Denis

AU - Lenhoff, Stig

AU - Udvardy, M.

AU - Crawley, Charles

AU - Arcese, William

AU - Mariette, Clara

AU - Hunter, Ann

AU - Leleu, Xavier

AU - Schipperus, Martin

AU - Delforge, Michel

AU - Pioltelli, Pietro

AU - Snowden, John A.

AU - Itälä-Remes, Maija

AU - Musso, Maurizio

AU - van Biezen, Anja

AU - Garderet, Laurent

AU - Kröger, Nicolaus

PY - 2018/4/30

Y1 - 2018/4/30

N2 - We investigated extramedullary disease in newly diagnosed multiple myeloma patients and its impact on outcome following first-line autologous stem cell transplantation. We identified 3744 adult myeloma patients who received up-front single (n=3391) or tandem transplantation (n=353) between 2005 and 2014 with available data on extramedullary involvement at diagnosis. The overall incidence of extramedullary disease was 18.2% (n=682) and increased per year from 6.5% (2005) to 23.7% (2014). Paraskeletal involvement was found in 543 (14.5%) and extramedullary organ involvement in 139 (3.7%). More patients with extramedullary organ involvement had multiple involved sites (≥2; P<0.001). In a comparison of patients with single sites with patients without the disease, up-front transplantation resulted in at least similar 3-year progression-free survival (paraskeletal: P=0.86, and extramedullary organ: P=0.88). In single paraskeletal involvement, this translated less clearly into worse 3-year overall survival (P=0.07) while single organ involvement was significantly worse (P=0.001). Multiple organ sites were associated with worse outcome (P<0.001 and P=0.01). First-line treatment with tandem compared with single transplantation resulted in similar survival in patients with extramedullary disease at diagnosis (P=0.13 for both).

AB - We investigated extramedullary disease in newly diagnosed multiple myeloma patients and its impact on outcome following first-line autologous stem cell transplantation. We identified 3744 adult myeloma patients who received up-front single (n=3391) or tandem transplantation (n=353) between 2005 and 2014 with available data on extramedullary involvement at diagnosis. The overall incidence of extramedullary disease was 18.2% (n=682) and increased per year from 6.5% (2005) to 23.7% (2014). Paraskeletal involvement was found in 543 (14.5%) and extramedullary organ involvement in 139 (3.7%). More patients with extramedullary organ involvement had multiple involved sites (≥2; P<0.001). In a comparison of patients with single sites with patients without the disease, up-front transplantation resulted in at least similar 3-year progression-free survival (paraskeletal: P=0.86, and extramedullary organ: P=0.88). In single paraskeletal involvement, this translated less clearly into worse 3-year overall survival (P=0.07) while single organ involvement was significantly worse (P=0.001). Multiple organ sites were associated with worse outcome (P<0.001 and P=0.01). First-line treatment with tandem compared with single transplantation resulted in similar survival in patients with extramedullary disease at diagnosis (P=0.13 for both).

UR - http://www.scopus.com/inward/record.url?scp=85046343638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046343638&partnerID=8YFLogxK

U2 - 10.3324/haematol.2017.178434

DO - 10.3324/haematol.2017.178434

M3 - Article

AN - SCOPUS:85046343638

VL - 103

SP - 890

EP - 897

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -